Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
Status: | Active, not recruiting |
---|---|
Conditions: | Breast Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 3/16/2019 |
Start Date: | March 29, 2014 |
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
This randomized phase III trial studies exemestane and entinostat to see how well they work
compared to exemestane alone in treating patients with hormone receptor-positive breast
cancer that has spread to nearby tissue or lymph nodes or another place in the body. Estrogen
can cause the growth of breast cancer cells. Endocrine therapy using exemestane may fight
breast cancer by lowering the amount of estrogen the body makes. Entinostat may stop the
growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet
known whether exemestane is more effective with or without entinostat in treating breast
cancer.
compared to exemestane alone in treating patients with hormone receptor-positive breast
cancer that has spread to nearby tissue or lymph nodes or another place in the body. Estrogen
can cause the growth of breast cancer cells. Endocrine therapy using exemestane may fight
breast cancer by lowering the amount of estrogen the body makes. Entinostat may stop the
growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet
known whether exemestane is more effective with or without entinostat in treating breast
cancer.
PRIMARY OBJECTIVES:
I. To evaluate whether the addition of entinostat to endocrine therapy (exemestane) improves
progression-free survival (PFS) and/or overall survival (OS) in patients with hormone
receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally
advanced or metastatic breast cancer who have previously progressed on a non-steroidal
aromatase inhibitor (Al).
SECONDARY OBJECTIVES:
I. To evaluate the safety and tolerability of entinostat in combination with exemestane, and
to compare the safety profile to that of endocrine therapy with placebo.
II. To evaluate the objective response rate of exemestane in combination with entinostat or
placebo.
III. To evaluate whether the efficacy of exemestane with entinostat varies with changes in
acetylation status in peripheral blood mononuclear cells (PBMCs).
IV. To evaluate the time to treatment deterioration (as defined by decrease in health-related
quality of life [HRQL], progression, death) of exemestane + entinostat versus exemestane +
placebo arms.
V. To evaluate the differences in overall health-related quality of life (HRQL) between the
exemestane + entinostat versus exemestane + placebo arms.
VI. To evaluate the difference with respect to specific symptoms that are associated with
entinostat, i.e., fatigue, nausea, anorexia and diarrhea, between the exemestane + entinostat
versus exemestane + placebo arms.
VII. To measure adherence to protocol therapy. VIII. To evaluate the pharmacokinetics of
entinostat in patients with advanced breast cancer.
IX. To evaluate what, if any, patient variables alter the pharmacokinetic profile of
entinostat in patients with advanced breast cancer.
EXPLORATORY OBJECTIVES:
I. To collect archival tumor samples and germline deoxyribonucleic acid (DNA) to explore
other potential biomarkers of therapeutic efficacy.
II. To collect patient ratings of adverse events (AEs) using select patient-reported outcomes
(PRO)-Common Terminology Criteria for Adverse Events (CTCAE) items to evaluate the
psychometric properties of PRO-CTCAE items and explore the incorporation of PRO-CTCAE items
into a phase III double-blind placebo-controlled trial.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM A: Patients receive exemestane orally (PO) once daily (QD) on days 1-28 and entinostat PO
on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression
or unacceptable toxicity.
ARM B: Patients receive exemestane as in Arm A and placebo PO on days 1, 8, 15, and 22.
Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
In both arms, pre/perimenopausal female patients and all male patients also receive goserelin
acetate subcutaneously (SC) on day 1.
After completion of study treatment, patients are followed up every 3 months for 2 years,
every 6 months for 3 years, and then annually for 5 years.
I. To evaluate whether the addition of entinostat to endocrine therapy (exemestane) improves
progression-free survival (PFS) and/or overall survival (OS) in patients with hormone
receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally
advanced or metastatic breast cancer who have previously progressed on a non-steroidal
aromatase inhibitor (Al).
SECONDARY OBJECTIVES:
I. To evaluate the safety and tolerability of entinostat in combination with exemestane, and
to compare the safety profile to that of endocrine therapy with placebo.
II. To evaluate the objective response rate of exemestane in combination with entinostat or
placebo.
III. To evaluate whether the efficacy of exemestane with entinostat varies with changes in
acetylation status in peripheral blood mononuclear cells (PBMCs).
IV. To evaluate the time to treatment deterioration (as defined by decrease in health-related
quality of life [HRQL], progression, death) of exemestane + entinostat versus exemestane +
placebo arms.
V. To evaluate the differences in overall health-related quality of life (HRQL) between the
exemestane + entinostat versus exemestane + placebo arms.
VI. To evaluate the difference with respect to specific symptoms that are associated with
entinostat, i.e., fatigue, nausea, anorexia and diarrhea, between the exemestane + entinostat
versus exemestane + placebo arms.
VII. To measure adherence to protocol therapy. VIII. To evaluate the pharmacokinetics of
entinostat in patients with advanced breast cancer.
IX. To evaluate what, if any, patient variables alter the pharmacokinetic profile of
entinostat in patients with advanced breast cancer.
EXPLORATORY OBJECTIVES:
I. To collect archival tumor samples and germline deoxyribonucleic acid (DNA) to explore
other potential biomarkers of therapeutic efficacy.
II. To collect patient ratings of adverse events (AEs) using select patient-reported outcomes
(PRO)-Common Terminology Criteria for Adverse Events (CTCAE) items to evaluate the
psychometric properties of PRO-CTCAE items and explore the incorporation of PRO-CTCAE items
into a phase III double-blind placebo-controlled trial.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM A: Patients receive exemestane orally (PO) once daily (QD) on days 1-28 and entinostat PO
on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression
or unacceptable toxicity.
ARM B: Patients receive exemestane as in Arm A and placebo PO on days 1, 8, 15, and 22.
Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
In both arms, pre/perimenopausal female patients and all male patients also receive goserelin
acetate subcutaneously (SC) on day 1.
After completion of study treatment, patients are followed up every 3 months for 2 years,
every 6 months for 3 years, and then annually for 5 years.
Inclusion Criteria:
- Estrogen receptor (ER) and/or progesterone receptor (PR) positive histologically
confirmed adenocarcinoma of the breast with staining of >= 1% cells will be considered
positive; receptor status may be based on any time during treatment prior to study
randomization, and from any site (i.e. primary, recurrent, or metastatic)
- Patients whose tumors have HER2 immunohistochemistry (IHC) 3+, in situ hybridization
(ISH) >= 2.0, or average HER2 copy number >= 6.0 signals per cell are not eligible;
receptor status may be based on any time during treatment prior to study
randomization, and from any site (i.e. primary, recurrent, or metastatic)
- Patients must have measurable or non-measurable stage III/locally advanced or
metastatic carcinoma of the breast where local therapy with curative intent is not
possible; lesions must be evaluated =< 4 weeks prior to study randomization;
diagnostic-quality computed tomography (CT) scans with both oral and intravenous (IV)
contrast are the expected radiologic method, unless an alternative is approved
- NOTE: Where baseline imaging has already been performed =< 6 weeks prior to study
randomization, repeat imaging may not be required
- NOTE: As of October 16, 2016, accrual of new patients having non-measurable
disease has stopped; the planned accrual for this target population has been
reached
- Pre/peri- and postmenopausal women and all men are eligible for this trial;
postmenopausal is defined as:
- Age >= 55 years and one year or more of amenorrhea
- Age < 55 years and one year or more of amenorrhea, with estradiol < 20 pg/ml
- Age < 55 with prior hysterectomy but intact ovaries, with estradiol < 20 pg/ml
- Prior bilateral oophorectomy
- NOTE: Women who do not fit the criteria for being postmenopausal as above
are deemed pre-or peri-menopausal; pre/perimenopausal women and all men can
enroll provided they agree to receive concomitant luteinizing
hormone-releasing hormone (LHRH) agonist; pre/perimenopausal women must have
commenced treatment with LHRH agonist at least 4 weeks prior to
randomization; if patients have received alternative LHRH agonist prior to
study entry, they must switch to goserelin for the duration of the trial
- Sexually active males and pre/perimenopausal women must agree to use an accepted and
effective method of contraception or to abstain from sexual intercourse for the
duration of their participation in the study and for 3 months after discontinuation of
therapy
- Women must not be pregnant or breast-feeding; all females of childbearing potential
must have a blood test or urine study =< 2 weeks prior to randomization
- A female of childbearing potential is any woman, regardless of sexual orientation
or whether they have undergone tubal ligation, who meets the following criteria:
1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been
naturally postmenopausal for at least 24 consecutive months (i.e., has had menses
at any time in the preceding 24 consecutive months)
- Patients must not have known central nervous system metastasis or a history of central
nervous system (CNS) metastases; patients with leptomeningeal disease are not eligible
- Patients must be disease-free of prior invasive malignancies for > 5 years with the
exception of curatively-treated basal cell or squamous cell carcinoma of the skin or
carcinoma in situ of the cervix
- NOTE: If there is a history of prior malignancy, patients must not be receiving
other specific treatment for that cancer
- Patients must meet at least one of the following criteria:
- Disease progression any time after non-steroidal AI use in the advanced disease
setting
- Relapse while on or within =< 12 months of end of adjuvant non-steroidal AI
therapy with or without prior endocrine therapy for advanced disease
- NOTE: In either setting, treatment with any prior endocrine therapy must be
completed >= 2 weeks prior to course 1 day 1 (C1D1) of study treatment with the
exception of exemestane which is permitted in the advanced disease setting within
=< 4 weeks immediately prior to C1D1; prior adjuvant exemestane is allowed if the
disease free interval is > 12 months from the discontinuation of exemestane;
prior faslodex, everolimus, palbociclib or other cyclin-dependent kinase (CDK)
inhibitor (e.g. ribociclib, abemaciclib) use are allowed and must have been
completed >= 2 weeks prior to C1D1; failure to adhere to this washout guideline
will result in a protocol violation
- Patients may have received only one prior chemotherapy regimen for metastatic disease
provided treatment was completed >= 3 weeks prior to randomization
- Patients may be treated with bone modifying agents such as bisphosphonates or
RANK-ligand agents (e.g. denosumab) per American Society of Clinical Oncology (ASCO)
guidelines; whenever possible, patients requiring bone modifying agents should start
treatment >= 7 days prior to study therapy and should continue the same agent
throughout study unless clinically compelled to change
- Prior radiotherapy must in general have been completed >= 2 weeks prior to
randomization and patients must have recovered from the toxicity of the radiation
- NOTE: Patients may receive concurrent radiation therapy to painful sites of bony
disease or areas of impending fracture as long as sites of measurable or
non-measurable disease outside the radiation therapy port are available to follow
- Patients must NOT receive concurrent anti-cancer therapy or investigational agent
unless specified in protocol
- Patients must NOT be receiving valproic acid, an histone deacetylase (HDAC) inhibitor,
and may not have previously received any HDAC inhibitor prior to enrollment (e.g.
valproic acid, entinostat, vorinostat) unless discussed with the study chair; patients
must not have received prior HDAC therapy for the treatment of their malignancy
- Patients must have no known allergies to exemestane, entinostat, or medications that
have a benzamide structure (e.g., tiapride, remoxipride, clebropride)
- Patients must NOT suffer from medical or psychiatric conditions that would interfere
with protocol compliance, the ability to provide informed consent, or assessment of
response or anticipated toxicities; this includes uncontrolled intercurrent illness
including, but not limited to ongoing or active infection
- Patients must have recovered from all clinically relevant adverse events to grade 1 or
baseline due to previous agents administered (except alopecia)
- Patients must have adequate hematologic, liver and renal function =< 28 days prior to
randomization
- NOTE: It is preferred that laboratory values for eligibility be assessed after
the last dose of prior treatment, especially in cases where most-recent treatment
prior to study entry is chemotherapy
- Hemoglobin (HgB) >= 9.0 g/dL (=< 28 days prior to randomization)
- Platelet count >= 100,000/mcL (=< 28 days prior to randomization)
- Absolute neutrophil count >= 1,500/mcL (=< 28 days prior to randomization)
- Creatinine =< 2.0 mg/dL (=< 28 days prior to randomization)
- Total bilirubin < 1.5 x institutional upper limit of normal (=< 3 mg/dL in case of
Gilbert's syndrome) (=< 28 days prior to randomization)
- Transaminases (alanine aminotransferase [ALT], aspartate aminotransferase [AST]) =<
2.5 x institutional upper limit normal (=< 28 days prior to randomization)
- Known human immunodeficiency virus (HIV)-positive patients should have a cluster of
differentiation (CD)4 count > 250/mm^3
- Patients must have Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Patients must have a life expectancy >= 12 weeks
- Patients must be able to swallow tablets
We found this trial at
664
sites
1305 W 18th St
Sioux Falls, South Dakota 57117
Sioux Falls, South Dakota 57117
(605) 333-1000
![Sanford USD Medical Center - Sioux Falls](/wp-content/uploads/logos/sanford-usd-medical-center---sioux-falls.jpg)
Principal Investigator: Preston D. Steen
Phone: 605-312-3320
Sanford USD Medical Center - Sioux Falls Sanford
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
1201 Camino de Salud Northeast
Albuquerque, New Mexico 87131
Albuquerque, New Mexico 87131
(505) 272-4946
![University of New Mexico Cancer Center](/wp-content/uploads/logos/university-of-new-mexico-cancer-center.jpg)
Principal Investigator: Ursa A. Brown-Glaberman
Phone: 505-925-0366
University of New Mexico Cancer Center It’s been 40 years since the New Mexico State...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
361 Old Belgrade Road
Augusta, Maine 04330
Augusta, Maine 04330
(207) 621-6100
![Harold Alfond Center for Cancer Care](/wp-content/uploads/logos/harold-alfond-center-for-cancer-care.png)
Principal Investigator: Thomas H. Openshaw
Phone: 207-626-4855
Harold Alfond Center for Cancer Care MaineGeneral's Harold Alfond Center for Cancer Care (HACCC) is...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Bremerton, Washington 98310
Principal Investigator: Mehmet S. Copur
Phone: 308-398-6518
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
666 Elm Street
Buffalo, New York 14263
Buffalo, New York 14263
(716) 845-2300
![Roswell Park Cancer Institute](/wp-content/uploads/logos/roswell-park-cancer-institute.jpg)
Principal Investigator: Ellis G. Levine
Phone: 800-767-9355
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
1300 Jefferson Park Avenue
Charlottesville, Virginia 22908
Charlottesville, Virginia 22908
434-243-6784
![University of Virginia Cancer Center](/wp-content/uploads/logos/university-of-virginia-cancer-center.jpg)
Principal Investigator: Christiana M. Brenin
Phone: 434-243-6303
University of Virginia Cancer Center We are fortunate in having state of the art clinical...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
1 Hurley Plaza
Flint, Michigan 48503
Flint, Michigan 48503
(810) 262-9000
![Hurley Medical Center](/wp-content/uploads/logos/hurley-medical-center.png)
Principal Investigator: Christopher M. Reynolds
Phone: 734-712-3671
Hurley Medical Center From its founding in 1908, Hurley Medical Center has devoted itself to...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
2500 N State St
Jackson, Mississippi 39216
Jackson, Mississippi 39216
(601) 984-1000
![University of Mississippi Medical Center](/wp-content/uploads/logos/university-of-mississippi-medical-center.png)
Principal Investigator: Barbara S. Craft
Phone: 601-815-6700
University of Mississippi Medical Center The University of Mississippi Medical Center, located in Jackson, is...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
200 North Park Street
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49007
(269) 382-2500
![West Michigan Cancer Center](/wp-content/uploads/logos/west-michigan-cancer-center.png)
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
West Michigan Cancer Center In 1994, Borgess Health Alliance and Bronson Healthcare Group opened the...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
777 Hemlock Street
Macon, Georgia 31201
Macon, Georgia 31201
(478) 633-1000
![Medical Center of Central Georgia](/wp-content/uploads/logos/medical-center-of-central-georgia.jpg)
Principal Investigator: Bradley T. Sumrall
Phone: 478-633-2152
Medical Center of Central Georgia Navicent Health is a designated Level I Trauma Center and...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
4805 Northeast Glisan Street
Portland, Oregon 97213
Portland, Oregon 97213
(503) 215-1111
![Providence Portland Medical Center](/wp-content/uploads/logos/providence-portland-medical-center.png)
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
Providence Portland Medical Center We strive to give those we serve exceptional, compassionate health care...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
401 College Street
Richmond, Virginia 23298
Richmond, Virginia 23298
(804) 828-0450
![Virginia Commonwealth University Massey Cancer Center](/wp-content/uploads/logos/virginia-commonwealth-university-massey-cancer-center.jpg)
Principal Investigator: Hetal R. Vachhani
Phone: 804-628-1939
Virginia Commonwealth University Massey Cancer Center Founded in 1974, VCU Massey Cancer Center is a...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
60 Crittenden Blvd # 70
Rochester, New York 14642
Rochester, New York 14642
(585) 275-2121
![University of Rochester](/wp-content/uploads/logos/university-of-rochester.png)
Principal Investigator: Paul M. Barr
Phone: 585-275-5830
University of Rochester The University of Rochester is one of the country's top-tier research universities....
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
1100 Fairview Avenue North
Seattle, Washington 98109
Seattle, Washington 98109
(206) 667-5000
![Fred Hutchinson Cancer Research Center](/wp-content/uploads/logos/fred-hutchinson-cancer-research-center.gif)
Principal Investigator: Hannah M. Linden
Phone: 800-804-8824
Fred Hutchinson Cancer Research Center At Fred Hutchinson Cancer Research Center, our interdisciplinary teams of...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
825 Eastlake Ave E
Seattle, Washington 98109
Seattle, Washington 98109
(206) 288-7222
![Seattle Cancer Care Alliance](/wp-content/uploads/logos/seattle-cancer-care-alliance.jpg)
Principal Investigator: Hannah M. Linden
Phone: 800-804-8824
Seattle Cancer Care Alliance Seattle Cancer Care Alliance (SCCA) is a cancer treatment center that...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
3900 W Avera Drive
Sioux Falls, South Dakota 57108
Sioux Falls, South Dakota 57108
(605) 322-4700
![Avera Cancer Institute](/wp-content/uploads/logos/avera-cancer-institute.jpg)
Principal Investigator: Amy K. Krie
Phone: 888-634-7268
Avera Cancer Institute Avera, the health ministry of the Benedictine and Presentation Sisters, is a...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
808 North 39th Avenue
Yakima, Washington 98902
Yakima, Washington 98902
Principal Investigator: Keith S. Lanier
Phone: 503-215-6412
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
'Aiea, Hawaii 96701
Principal Investigator: Jeffrey L. Berenberg
Phone: 808-487-7447
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
98-1079 Moanalua Road
'Aiea, Hawaii 96701
'Aiea, Hawaii 96701
Principal Investigator: Jeffrey L. Berenberg
Phone: 808-486-6000
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Aberdeen, South Dakota 57401
Principal Investigator: Amy K. Krie
Phone: 605-622-8700
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Adrian, Michigan 49221
Principal Investigator: Rex B. Mowat
Phone: 517-265-0116
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
1 Akron General Avenue
Akron, Ohio 44307
Akron, Ohio 44307
Principal Investigator: Esther H. Rehmus
Phone: 866-223-8100
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Albuquerque, New Mexico 87109
Principal Investigator: Ursa A. Brown-Glaberman
Phone: 505-272-0530
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Ames, Iowa 50010
Principal Investigator: Joseph J. Merchant
Phone: 515-239-2621
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
2000 E Greenville St
Anderson, South Carolina 29621
Anderson, South Carolina 29621
(864) 512-4640
![AnMedical Health Cancer Center](/wp-content/uploads/logos/anmedical-health-cancer-center.jpg)
Principal Investigator: John E. Doster
Phone: 864-512-4651
AnMedical Health Cancer Center Cancer is the general term for a group of more than...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
5301 McAuley Drive
Ann Arbor, Michigan 48197
Ann Arbor, Michigan 48197
734-712-3456
![Saint Joseph Mercy Hospital](/wp-content/uploads/logos/saint-joseph-mercy-hospital.jpg)
Principal Investigator: Christopher M. Reynolds
Phone: 734-712-3671
Saint Joseph Mercy Hospital St. Joseph Mercy Ann Arbor Hospital is a 537-bed teaching hospital...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Annapolis, Maryland 21401
Principal Investigator: Jeanine L. Werner
Phone: 443-481-1320
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Antigo, Wisconsin 54409
Principal Investigator: Harish G. Ahuja
Phone: 715-623-9869
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
364 White Oak St
Asheboro, North Carolina 27203
Asheboro, North Carolina 27203
(336) 625-5151
![Randolph Hospital](/wp-content/uploads/logos/randolph-hospital.png)
Principal Investigator: Vinay K. Gudena
Phone: 336-832-0836
Randolph Hospital Since 1932, Randolph Hospital has been fortunate to employ dedicated and loyal personnel...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Asheville, North Carolina 28801
Principal Investigator: Cameron B. Harkness
Phone: 828-670-8403
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Asheville, North Carolina 28801
Principal Investigator: Cameron B. Harkness
Phone: 828-670-8403
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Asheville, North Carolina 28816
Principal Investigator: Cameron B. Harkness
Phone: 828-670-8403
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Atlanta, Georgia 30303
Principal Investigator: Jane L. Meisel
Phone: 404-489-9164
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
550 Peachtree St NE
Atlanta, Georgia 30308
Atlanta, Georgia 30308
(404) 686-4411
![Emory University Hospital Midtown](/wp-content/uploads/logos/emory-university-hospital-midtown.png)
Principal Investigator: Jane L. Meisel
Phone: 888-946-7447
Emory University Hospital Midtown Emory University Hospital Midtown is a 511-bed community-based, acute care teaching...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Atlanta, Georgia 30322
Principal Investigator: Jane L. Meisel
Phone: 404-778-1868
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Auburn, New York 13021
Principal Investigator: Jeffrey J. Kirshner
Phone: 315-472-7504
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Aurora, Colorado 80012
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
1501 S Potomac St
Aurora, Colorado 80012
Aurora, Colorado 80012
(303) 695-2600
![Medical Center of Aurora](/wp-content/uploads/logos/medical-center-of-aurora.jpg)
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Medical Center of Aurora At The Medical Center of Aurora and Centennial Medical Plaza patients...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
2000 Ogden Ave
Aurora, Illinois 60504
Aurora, Illinois 60504
(630) 978-6200
![Rush - Copley Medical Center](/wp-content/uploads/logos/rush---copley-medical-center.png)
Principal Investigator: Kendrith M. Rowland
Phone: 630-978-6212
Rush - Copley Medical Center Rush-Copley is proud to be the leading provider of health...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Ballwin, Missouri 63011
Principal Investigator: Jay W. Carlson
Phone: 314-251-7058
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Baltimore, Maryland 21237
Principal Investigator: Yvonne L. Ottaviano
Phone: 443-777-7364
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
22 South Greene Street
Baltimore, Maryland 21201
Baltimore, Maryland 21201
410-328-7904
![University of Maryland Greenebaum Cancer Center](/wp-content/uploads/logos/university-of-maryland-greenebaum-cancer-center.jpg)
Principal Investigator: Katherine H. Tkaczuk
Phone: 800-888-8823
University of Maryland Greenebaum Cancer Center The University of Maryland Marlene and Stewart Greenebaum Cancer...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
401 North Broadway
Baltimore, Maryland 21287
Baltimore, Maryland 21287
410-955-5000
![Johns Hopkins University-Sidney Kimmel Cancer Center](/wp-content/uploads/logos/johns-hopkins-university-sidney-kimmel-cancer-center.png)
Principal Investigator: Roisin M. Connolly
Phone: 410-955-8804
Johns Hopkins University-Sidney Kimmel Cancer Center The name Johns Hopkins has become synonymous with excellence...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
6701 N Charles St
Baltimore, Maryland 21204
Baltimore, Maryland 21204
(443) 849-2000
![Greater Baltimore Medical Center](/wp-content/uploads/logos/greater-baltimore-medical-center.png)
Principal Investigator: Madhu Chaudhry
Phone: 443-849-3706
Greater Baltimore Medical Center The 255-bed medical center (acute and sub-acute care) is located on...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
2401 W Belvedere Ave
Baltimore, Maryland 21215
Baltimore, Maryland 21215
(410) 601-9000
![Sinai Hospital of Baltimore](/wp-content/uploads/logos/sinai-hospital-of-baltimore.jpg)
Principal Investigator: Marvin J. Feldman
Phone: 410-601-6120
Sinai Hospital of Baltimore Sinai Hospital of Baltimore provides a broad array of high-quality, cost-effective...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
489 State St
Bangor, Maine 04401
Bangor, Maine 04401
(207) 973-7000
![Eastern Maine Medical Center](/wp-content/uploads/logos/eastern-maine-medical-center.png)
Principal Investigator: Thomas H. Openshaw
Phone: 207-973-4274
Eastern Maine Medical Center Located in Bangor, Eastern Maine Medical Center (EMMC) serves communities throughout...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
4305 New Shepherdsville Road
Bardstown, Kentucky 40004
Bardstown, Kentucky 40004
Principal Investigator: Mehmet S. Copur
Phone: 308-398-6518
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Baton Rouge, Louisiana 70805
Principal Investigator: David S. Hanson
Phone: 225-215-1353
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Baton Rouge, Louisiana 70806
Principal Investigator: Hana F. Safah
Phone: 225-767-0822
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Baton Rouge, Louisiana 70809
Principal Investigator: David S. Hanson
Phone: 225-215-1353
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Baton Rouge, Louisiana 70809
Principal Investigator: David S. Hanson
Phone: 225-215-1353
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
4950 Essen Lane
Baton Rouge, Louisiana 70809
Baton Rouge, Louisiana 70809
Principal Investigator: David S. Hanson
Phone: 225-215-1353
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Baton Rouge, Louisiana 70809
Principal Investigator: John T. Cole
Phone: 225-761-5346
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Baton Rouge, Louisiana 70816
Principal Investigator: John T. Cole
Phone: 225-761-5346
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
800 Farson Street
Belpre, Ohio 45714
Belpre, Ohio 45714
(740) 401-0417
![Strecker Cancer Center-Belpre](/wp-content/uploads/logos/strecker-cancer-center-belpre.jpg)
Principal Investigator: Timothy D. Moore
Phone: 800-523-3977
Strecker Cancer Center-Belpre The Memorial Health System's Strecker Cancer Center, Belpre combines the clinical expertise...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Bend, Oregon 97701
Principal Investigator: Alison K. Conlin
Phone: 541-706-2909
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Beverly, Massachusetts 01915
Principal Investigator: James E. Liebmann
Phone: 978-922-3000
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
1233 North 30th Street
Billings, Montana 59101
Billings, Montana 59101
406-237-7000
![Saint Vincent Healthcare](/wp-content/uploads/logos/saint-vincent-healthcare.png)
Principal Investigator: Keren Sturtz
Phone: 406-969-6060
Saint Vincent Healthcare The Sisters of Charity of Leavenworth, Kansas, founded St. Vincent Healthcare in...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Birmingham, Alabama 35233
Principal Investigator: Carla I. Falkson
Phone: 205-934-0220
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
300 N. Seventh St.
Bismarck, North Dakota 58501
Bismarck, North Dakota 58501
(701) 323-6000
![Sanford Bismarck Medical Center](/wp-content/uploads/logos/sanford-bismarck-medical-center.jpg)
Principal Investigator: Preston D. Steen
Phone: 701-323-5760
Sanford Bismarck Medical Center Whether your stay in our hospital is one day for same...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Bloomington, Illinois 61701
Principal Investigator: James L. Wade
Phone: 217-876-4740
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
1505 Eastland Drive
Bloomington, Illinois 61701
Bloomington, Illinois 61701
309-662-2102
![Illinois CancerCare-Bloomington](/wp-content/uploads/logos/illinois-cancercare-bloomington.gif)
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare-Bloomington Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood diseases. Our...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Boise, Idaho 83706
Principal Investigator: Christopher M. Reynolds
Phone: 734-712-3671
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
100 E Idaho St
Boise, Idaho 83712
Boise, Idaho 83712
(208) 381-2711
![Saint Luke's Mountain States Tumor Institute](/wp-content/uploads/logos/saint-luke-s-mountain-states-tumor-institute.gif)
Principal Investigator: Alison K. Conlin
Saint Luke's Mountain States Tumor Institute For more than 100 years, St. Luke
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Bonne Terre, Missouri 63628
Principal Investigator: Bryan A. Faller
Phone: 314-996-5569
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Boone, Iowa 50036
Principal Investigator: Joseph J. Merchant
Phone: 515-239-2621
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
1100 Balsam Ave
Boulder, Colorado 80304
Boulder, Colorado 80304
(303) 440-2273
![Boulder Community Hospital](/wp-content/uploads/logos/boulder-community-hospital.jpg)
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Boulder Community Hospital Founded in 1922 as a community-owned and operated not-for-profit hospital, Boulder Community...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Boulder, Colorado 80303
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Toledo Clinic Cancer Centers-Bowling Green Our doctors evaluate and make recommendations regarding cancer treatment for...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
915 Highland Blvd
Bozeman, Montana 59715
Bozeman, Montana 59715
(406) 414-5000
![Bozeman Deaconess Hospital](/wp-content/uploads/logos/bozeman-deaconess-hospital.jpg)
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Bozeman Deaconess Hospital Bozeman Deaconess Hospital is a Joint Commission certified, licensed Level III trauma...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Brainerd, Minnesota 56401
Principal Investigator: Bret E. Friday
Phone: 888-203-7267
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Branson, Missouri 65616
Principal Investigator: Jay W. Carlson
Phone: 417-269-4520
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Bremerton, Washington 98310
Principal Investigator: Mehmet S. Copur
Phone: 308-398-6518
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Brewer, Maine 04412
Principal Investigator: Thomas H. Openshaw
Phone: 800-987-3005
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Bronx, New York 10461
Principal Investigator: Della F. Makower
Phone: 718-379-6866
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Bronx, New York 10461
Principal Investigator: Della F. Makower
Phone: 718-379-6866
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Bronx, New York 10467
Principal Investigator: Della F. Makower
Phone: 718-379-6866
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Brownstown, Michigan 48183
Principal Investigator: Ding Wang
Phone: 888-823-5923
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
130 S Bryn Mawr Ave
Bryn Mawr, Pennsylvania 19010
Bryn Mawr, Pennsylvania 19010
(484) 337-3000
![Bryn Mawr Hospital](/wp-content/uploads/logos/bryn-mawr-hospital.png)
Principal Investigator: Albert S. DeNittis
Phone: 484-476-2649
Bryn Mawr Hospital Bryn Mawr Hospital, a nationally recognized community teaching hospital, is conveniently located...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Burien, Washington 98166
Principal Investigator: Mehmet S. Copur
Phone: 308-398-6518
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Burlington, Massachusetts 01805
Principal Investigator: Corrine L. Zarwan
Phone: 781-744-8027
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Burlington, North Carolina 27216
Principal Investigator: Vinay K. Gudena
Phone: 336-538-7725
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Burlington, Wisconsin 53105
Principal Investigator: Rubina Qamar
Phone: 414-302-2304
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
400 South Clark Street
Butte, Montana 59701
Butte, Montana 59701
406-723-2500
![Saint James Community Hospital and Cancer Treatment Center](/wp-content/uploads/logos/saint-james-community-hospital-and-cancer-treatment-center.png)
Principal Investigator: Keren Sturtz
Phone: 406-723-2621
Saint James Community Hospital and Cancer Treatment Center St. James Healthcare has played an important...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
210 W Walnut St
Canton, Illinois 61520
Canton, Illinois 61520
309-647-5240
![Illinois CancerCare - Canton](/wp-content/uploads/logos/illinois-cancercare---canton.jpg)
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare - Canton Illinois CancerCare is one of the largest private oncology and hematology...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
211 Saint Francis Drive
Cape Girardeau, Missouri 63703
Cape Girardeau, Missouri 63703
573-331-3000
![Saint Francis Medical Center](/wp-content/uploads/logos/saint-francis-medical-center.png)
Principal Investigator: Bryan A. Faller
Phone: 573-334-2230
Saint Francis Medical Center Saint Francis Medical Center is a 282-bed facility serving more than...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
789 Mt Auburn Rd
Cape Girardeau, Missouri 63703
Cape Girardeau, Missouri 63703
(573) 519-4725
![Southeast Cancer Center](/wp-content/uploads/logos/southeast-cancer-center.png)
Principal Investigator: Bryan A. Faller
Phone: 573-651-5550
Southeast Cancer Center SoutheastHEALTH is a far-reaching network of providers and facilities including Southeast Hospital...
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Cape May Court House, New Jersey 08210
Principal Investigator: Victor G. Vogel
Phone: 888-369-2427
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Carbondale, Illinois 62902
Principal Investigator: Bryan A. Faller
Phone: 618-457-5200
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Carmel, Indiana 46032
Principal Investigator: Kathy D. Miller
Phone: 317-278-5632
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Carmichael, California 95608
Principal Investigator: Sonia E. Reichert
Phone: 916-537-5237
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)